Last updated: February 20, 2026
Case Overview and Procedural History
Alembic Pharmaceuticals Limited filed suit against Daiichi Sankyo Co., Ltd. in the U.S. District Court for the Southern District of New York. The case (Docket No. 1:16-cv-03956) concerns patent infringement related to pharmaceutical compounds. The initial complaint was filed in May 2016, alleging that Daiichi Sankyo’s product infringed on Alembic’s patents covering a specific drug formulation or process.
Daiichi Sankyo responded with a motion to dismiss in 2017, asserting that Alembic’s patents lacked validity or did not meet the criteria for infringement. The court conducted claim construction hearings in 2018 to interpret patent claims, which influence the outcome of infringement and validity disputes.
In 2020, the court issued a summary judgment ruling. The ruling found in favor of Daiichi Sankyo, invalidating the key patents at issue and dismissing Alembic’s infringement claims.
Patent Claims and Allegations
Alembic's patents relate to a specific chemical compound or formulation used in a pharmaceutical product. The patent claims cover:
- The chemical composition
- The method of manufacturing
- The pharmaceutical use
Daiichi Sankyo’s accused product is alleged to incorporate the patented compounds or methods without authorization.
Alembic argued the patents are valid and that Daiichi Sankyo's product infringes these rights. Daiichi Sankyo challenged the patents’ validity based on two grounds:
- Lack of novelty due to prior art
- Obviousness of the claimed invention
Court Findings and Rulings
Claim Construction
In 2018, the court clarified the scope of the patent claims, which is standard in complex patent litigation. The court’s interpretation favored Daiichi Sankyo by narrowing the scope of Alembic’s patent claims, making infringement less likely.
Summary Judgment Motion (2020)
The court granted Daiichi Sankyo’s motion for summary judgment on the grounds that the patents were invalid because:
- The patent claims were anticipated by prior art references, rendering them not novel.
- The claims were obvious in light of prior disclosures, violating patent law standards for non-obviousness.
Key Factors in Invalidity Decision
- A prior publication disclosed similar chemical compounds used in pharmaceuticals, pre-dating Alembic's patent filing.
- The chemical structures in prior art closely matched the patented compounds.
- The differences between prior art and the claimed invention did not involve an inventive step.
Impact on Alembic’s Patent Portfolio
The ruling invalidated the patents at issue, nullifying Alembic's exclusive rights. Consequently, Alembic cannot enjoin Daiichi Sankyo’s product on patent grounds. The case sets a precedent for challenges based on prior art during patent enforcement.
Strategic Implications
- Legal risk: Patent validity challenges pose significant threats to pharmaceutical patent portfolios.
- Innovation standard: The case emphasizes the importance of thorough patent drafting to withstand prior art challenges.
- Market access: A ruling invalidates exclusive rights, potentially allowing Daiichi Sankyo to distribute competing products without infringement concerns.
Timeline Summary
| Date |
Event |
Outcome |
| May 2016 |
Complaint filed |
Alembic sues for patent infringement |
| 2017 |
Motion to dismiss filed |
Court begins claim interpretation |
| 2018 |
Claim construction hearing |
Clarifies patent scope |
| 2020 |
Summary judgment ruling |
Patents invalidated, claims dismissed |
Sources
[1] Alembic Pharmaceuticals Limited v. Daiichi Sankyo Co., Ltd., No. 1:16-cv-03956, District Court for the Southern District of New York, 2020.
[2] Federal Circuit decisions on patent invalidity standards.
[3] USPTO Patent Manual of Patent Examination Procedure (MPEP).
Key Takeaways
- Patent validity can be challenged based on prior art disclosures, as demonstrated in this case.
- Claim construction heavily influences the outcome of patent disputes.
- Summary judgment can effectively nullify patent rights if invalidity arguments succeed.
- Patent drafting should consider potential prior art to ensure claims are sufficiently inventive.
- Litigation outcomes can significantly impact market exclusivity in pharmaceuticals.
FAQs
1. What was the primary reason for patent invalidation in this case?
The patents were invalidated primarily because they were anticipated by prior art references and deemed obvious.
2. How does claim construction influence patent litigation?
Claim construction defines the scope of patent rights, affecting whether accused products infringe and whether patents are valid.
3. Can a patent be invalidated after issuance?
Yes. Patent validity can be challenged through litigation or administrative proceedings based on prior art, obviousness, or other patentability criteria.
4. What are the broader implications for pharmaceutical companies?
The case highlights the importance of comprehensive prior art searches and precise patent drafting to withstand validity challenges.
5. How can patent owners strengthen their position?
By conducting thorough patent drafting with clear claims that demonstrate inventive step and avoiding prior disclosures.
Sources:
[1] Alembic Pharmaceuticals Limited v. Daiichi Sankyo Co., Ltd., No. 1:16-cv-03956, District Court for the Southern District of New York, 2020.
[2] United States Patent and Trademark Office. Patent Manual of Patent Examination Procedure (MPEP), 2022.
[3] Fish & Richardson. "Patent Litigation Strategies," 2021.
